Skip to Content

Dormosedan (Canada)

This page contains information on Dormosedan for veterinary use.
The information provided typically includes the following:
  • Dormosedan Indications
  • Warnings and cautions for Dormosedan
  • Direction and dosage information for Dormosedan

Dormosedan

This treatment applies to the following species:
Company: Zoetis

(detomidine hydrochloride)

Veterinary Use Only

Injectable Sedative and Analgesic

Sterile Solution

10 mg/mL

DIN 01927027

Description

Dormosedan is a synthetic α2-adrenoceptor agonist with sedative and analgesic properties. The chemical name is 1H-imidazole, 4-[(2,3-dimethylphenyl)methyl]-hydrochloride and the generic name is detomidine hydrochloride. It is a white, crystalline, water-soluble substance having a molecular weight of 222.7. The molecular formula is C12H14N2•HCl.

CHEMICAL STRUCTURE:

Each mL of Dormosedan contains 10.0 mg detomidine hydrochloride (medicinal ingredient), 1.0 mg methyl paraben (preservative), 5.9 mg sodium chloride, and water for injection (USP), q.s.

Clinical Pharmacology

Dormosedan, a non-narcotic sedative and analgesic, is a potent α2-adrenoceptor agonist which produces sedation and superficial and visceral analgesia which is dose dependent in its depth and duration. Profound lethargy and a characteristic lowering of the head with reduced sensitivity to environmental stimuli (sounds, etc.) are seen with detomidine. A short period of incoordination is characteristically followed by immobility and a firm stance with front legs well spread. The analgesic effect is most readily seen as an increase in the pain threshold at the body surface. With IV administration, both superficial and visceral analgesia are seen to depths which allow for such procedures as flank incision after local anesthesia, penetration of the peritoneum, and rectal examinations for diagnosis of colic. Sensitivity to touch is little affected and in some cases may actually be enhanced.

Chemical restraint and pain relief provided by α2-adrenoceptors facilitates handling of fractious animals, and aids in the conduct of uncomfortable diagnostic or therapeutic procedures such as endoscopy, nasogastric tubing, and rectal examinations. It also facilitates surgical procedures (with or without local anesthesia) such as suturing of skin lacerations, flank incisions for ovariectomy, vaginal suturing, and castration.

With detomidine administration, heart rate is markedly decreased, blood pressure is initially elevated and then a steady decline to normal is seen. A transient change in the conductivity of the cardiac muscle may occur, as evidenced by partial atrioventricular (AV) and sinoauricular (SA) blocks. This change in the conductivity of the cardiac muscle may be prevented by IV administration of atropine at 0.02 mg/kg of body weight.

A diuretic effect is usually observed within 45 to 60 minutes after treatment. No effect on blood clotting time or other hematological parameters was encountered at dosages of 20 or 40 mcg/kg of body weight. Respiratory responses include an initial slowing of respiration within a few seconds to 1 to 2 minutes after administration, increasing to normal within 5 minutes. An initial decrease in tidal volume is followed by an increase.

Dormosedan Indications

Dormosedan is indicated for use as a sedative and analgesic to facilitate minor surgical and diagnostic procedures in mature horses and yearlings.

WARNINGS: This drug is not to be administered to horses that are to be slaughtered for use in food.

Keep out of reach of children.

Contraindications

Not to be used in horses with preexisting AV or SA block, with severe coronary insufficiency, cerebrovascular disease, respiratory disease, or chronic renal failure. Detomidine hydrochloride should not be used in breeding horses since the potential risk has not been assessed in either stallions or mares.

CAUTIONS: The drug is a potent α2-agonist which should be used with extreme caution with other sedatives, analgesics, or anesthetics as these are likely to produce additive effects. The use of epinephrine should be avoided, except in anesthetic emergency, since epinephrine may potentiate the effects of α2-agonists. Careful consideration should be given prior to the administration of Dormosedan to horses in endotoxic or traumatic shock or approaching shock, to horses with advanced liver or kidney disease or other preexisting conditions of stress such as extreme heat or cold, high altitude, or fatigue. Intravenous potentiated sulfonamides should not be used in anesthetized or sedated horses as potentially fatal dysrhythmias may occur. Protect treated horses from temperature extremes.

Food and water should be withheld until the sedative effect of Dormosedan has worn off.

NOTE TO USERS: Animals should not be left unattended during the development and duration of sedation. Allowing the horse to stand quietly for 5 minutes prior to and after injection may improve the response to Dormosedan. Some horses, although apparently deeply sedated, may still respond to external stimuli. Routine safety measures should be employed to protect practitioners and handlers.

Adverse Reactions

As with all α2-agonists, the potential for isolated cases of hypersensitivity, including paradoxical response (excitation) exists. There has been an occasional appearance of arrhythmia, hypertension, and bradycardia in horses treated with Dormosedan. Piloerection, sweating and salivation, and, occasionally, slight muscle tremors are seen after administration. Partial transient penis prolapse may be seen. Decreased heart and respiratory rates may occur. Incoordination or staggering is usually seen only during the first 3 to 5 minutes after injection, until animals have secured a firm footing. Because of continued lowering of the head during sedation, passive congestion may occur occasionally in the lips, the facial area, and the upper airways. Tying the head in a slightly elevated position generally prevents these effects.

POST APPROVAL EXPERIENCE: Although all adverse reactions are not reported, the following information is based on voluntary post-approval drug experience reporting. It is generally recognized that this results in under-reporting. The adverse events listed here reflect reported observations regardless of association with causality. Adverse events are listed by body system, in decreasing order of frequency:

Systemic disorders: Lethargy, hyperthermia

Neurological disorders: Ataxia, sedation and muscular tremors, loss of consciousness

Respiratory tract disorders: Tachypnea, dyspnea

Cardiovascular disorders: Tachycardia

Immune system disorders: Urticaria

Digestive tract disorders: Abdominal pain

Skin and appendages disorders: Hyperhidrosis

OVERDOSAGE: Detomidine hydrochloride is tolerated in horses at up to 200 mcg/kg of body weight (10 times the low dosage and 5 times the high dosage). In safety studies in horses, detomidine hydrochloride at 400 mcg/kg of body weight administered daily for 3 consecutive days produced microscopic foci of myocardial necrosis in 1 of 8 horses.

Dosage and Administration

Administer Dormosedan IV or IM at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 to 0.4 mL of Dormosedan per 100 kg or 220 lb), depending on the depth and duration of sedation and analgesia required. Analgesia is more pronounced when the drug is given IV. Sedative and analgesic effects will usually occur in 2 to 5 minutes and will persist for 30 minutes to 2 hours, depending on dosage and route of administration.

Prior to and following injection, the animal should be allowed to rest quietly. The full effect should be reached within 2 to 4 minutes after IV injection and 3 to 5 minutes after IM injection.

Storage

Store between 15 and 30°C in the absence of light. Content should be used within 90 days of the first puncture (20 punctures maximum).

How Supplied

Dormosedan is supplied in 5 and 20 mL, multidose vials containing 10 mg of detomidine hydrochloride per mL.

® Registered trademark of Orion Corporation; Zoetis Canada Inc., Licensee.

Canadian Patent Nos. 1154780 and 463626

Developed and manufactured by: Orion Pharma, Orion Corporation, Espoo, Finland

Distributed by: Zoetis Canada Inc., Kirkland QC H9H 4M7

107327-12

Made in Finland

6290-11-2

75-6290-22

CPN: 1198037.5

ZOETIS CANADA INC.
16,740 TRANS-CANADA HIGHWAY, KIRKLAND, QC, H9H 4M7
Order Desk:   800-663-8888
Technical Services Canada:   800-461-0917
Technical Services USA:   800-366-5288
Website:   www.zoetis.ca
Every effort has been made to ensure the accuracy of the Dormosedan information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2019 Animalytix LLC. Updated: 2019-09-30

Hide